MWNA
SUPN icon

Marshall Wace North America’s Supernus Pharmaceuticals SUPN Stock Holding History

Marshall Wace North America’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-63,084
Closed -$1.94M – 1705
2021
Q2 		$1.94M Buy
+63,084
New +$1.93M 0.01% 815
2020
Q4 		– Sell
-42,185
Closed -$880K – 1570
2020
Q3 		$880K Sell
42,185
-81,547
-66% -$1.85M 0.01% 836
2020
Q2 		$2.94M Buy
123,732
+97,769
+377% +$2.16M 0.02% 481
2020
Q1 		$468K Sell
25,963
-30,477
-54% -$640K ﹤0.01% 768
2019
Q4 		$1.34M Sell
56,440
-460,203
-89% -$11.2M 0.01% 664
2019
Q3 		$14.2M Buy
516,643
+14,860
+3% +$440K 0.08% 207
2019
Q2 		$16.6M Buy
501,783
+275,490
+122% +$9.44M 0.1% 170
2019
Q1 		$7.93M Buy
226,293
+60,880
+37% +$2.27M 0.06% 243
2018
Q4 		$5.5M Buy
+165,413
New +$7.11M 0.05% 238
2018
Q2 		– Sell
-79,058
Closed -$3.62M – 1668
2018
Q1 		$3.62M Buy
79,058
+46,318
+141% +$1.93M 0.02% 644
2017
Q4 		$1.3M Buy
+32,740
New +$1.29M 0.01% 938
2017
Q2 		– Sell
-15,101
Closed -$468K – 1454
2017
Q1 		$468K Buy
+15,101
New +$405K ﹤0.01% 824

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return

Marshall Wace North America's SUPN Position: Q3 2021 in Review

Marshall Wace North America sold out of Supernus Pharmaceuticals (SUPN) in Q3 2021, closing a stake of 63,084 shares — an estimated $1.94M sold.

Marshall Wace North America first reported a position in SUPN in Q1 2017 and held it in 12 quarters. The position peaked at $16.6M in Q2 2019. 223 funds tracked by Wall St. Rank hold SUPN as of Q3 2021.

  • Marshall Wace North America reported no remaining Supernus Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Marshall Wace North America sold 63,084 Supernus Pharmaceuticals shares in Q3 2021, an estimated $1.94M.
  • Marshall Wace North America first reported a position in Supernus Pharmaceuticals in Q1 2017 and held it in 12 quarters.
  • Marshall Wace North America's Supernus Pharmaceuticals position peaked at $16.6M in Q2 2019.
  • 223 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.